- Mubadala, the sovereign wealth fund of Abu Dhabi, and artificial intelligence firm G42 have created M42, a healthcare company with a "tech-enabled" approach, to improve medical research and facilities in the UAE's capital city. M42, which resulted from the merger of Mubadala and G42's healthcare units in October 2022, seeks to offer the best personalized, precise, and preventative care.
- The organization aims to partner with top researchers and HealthTech ecosystems, while considering global expansion and collaborations. Its portfolio includes many healthcare facilities like Amana Healthcare and Danat Al Emarat, specialty centers such as Moorfields Eye Hospital Abu Dhabi and Imperial College London Diabetes Centre.
Why it matters
The pandemic demonstrated the UAE's ability to endure as it enforced extensive health measures and a vaccine mandate. Additionally, Abu Dhabi is striving to establish itself as a leading global healthcare hub, with plans to create the world's first population-wide genetic library, focus on connected health, and expand on prior collaborations with pharmaceutical giants Pfizer and AstraZeneca in medical research.